Perimenopause- early identification and intervention w Dr Megan Ogilvie.
How comfortable are you managing Mary? She is 45, fit, still having regular periods, but struggling with poor sleep, anxiety and irritability. Is this stress, or the start of perimenopause?
Dr Louise Kuegler talks with reproductive endocrinologist Dr Megan Ogilvie about the early, often missed phase of the menopausal transition. Long before cycles become irregular, fluctuating hormones can drive mood change, worsening PMS and PMDD, migraines, joint pain and sleep disturbance, leaving many women feeling unlike themselves.
We explore why perimenopause is a time of heightened mood vulnerability, who is most at risk, and how to recognise symptoms that do not fit the classic teaching.
The discussion moves into practical primary care management, including when to consider SSRIs, the combined oral contraceptive pill, menopausal hormone therapy, or cycle suppression, and how to navigate the growing interest in natural therapies safely and realistically.
A clinically grounded, myth busting conversation designed to help you spot perimenopause earlier and treat with confidence.
Practical clinical pearls:
Early symptoms: Mood changes may precede menstrual changes and affect around 25 percent of women. Symptoms can mimic cardiology or rheumatology presentations.
Alternative preparations: These have a limited role. Use with caution and be aware of potential interactions.
Combined oral contraceptive pill: Can provide both symptom control and contraception.
Menopausal hormone therapy: Use initially as a cyclical trial, then consider moving to continuous therapy after six to twelve months. Review annually once stabilised. Always consider ongoing contraception needs. Investigate abnormal per vaginal bleeding.
Consider newer agents and cycle suppression for PMS and PMDD: Seek specialist input if needed.
Guest bio:
Dr Megan Ogilvie is Business Director at ERH Associates with subspecialty expertise in menopause, PCOS, athlete hormone health, PMS and PMDD, vasomotor symptoms, and gender affirming medicine.
Megan completed her endocrinology training in Auckland before undertaking a fellowship in London at St Bartholomew’s Hospital and University College London Hospitals. Since returning to New Zealand, she has worked in both general and reproductive endocrinology at Fertility Associates and Auckland District Health Board, and now at ERH Associates.
Her particular interests include menopause, polycystic ovarian syndrome, gender affirming care, athlete hormone health, and relative energy deficiency. Megan was a founding member of WHISPA, a medical advisory board to High Performance Sport New Zealand, and has delivered training workshops for High Performance Sport NZ in female athlete hormone health. She is the New Zealand representative on the board of the Australasian Menopause Society.
Resources:
https://www.menopause.org.au/hp/information-sheets/perimenopause
Magraith K, Stuckey B, Baber R. Perimenopausal Hormone Therapy Assessment and Prescribing. Medicine Today. 2022 August (23):61-67
Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. J Womens Health (Larchmt). 2019 Feb;28(2):117-134.
Faculty or Sexual and Reproductive Healthcare. FSRH Guideline for women aged over 40 years. Contraception for Women aged over 40 years. FSRH Clinical Effectiveness Unit; 2017(Amended 2025. (To download: https://www.fsrh.org/standards-and-guidance/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017/)
Email me:
Listen Here:
Spotify: https://open.spotify.com/episode/4dNQVKdaatG31dsnqfuDmt?si=kN4zYaI3SkegMntuWIWBVA
